Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1996 Oct;75(4):292–297. doi: 10.1136/adc.75.4.292

Final height in central precocious puberty after long term treatment with a slow release GnRH agonist.

W Oostdijk 1, B Rikken 1, S Schreuder 1, B Otten 1, R Odink 1, C Rouwé 1, M Jansen 1, W J Gerver 1, J Waelkens 1, S Drop 1
PMCID: PMC1511728  PMID: 8984913

Abstract

OBJECTIVE: To study the resumption of puberty and the final height achieved in children with central precocious puberty (CPP) treated with the GnRH agonist triptorelin. PATIENTS: 31 girls and five boys with CPP who were treated with triptorelin 3.75 mg intramuscularly every four weeks. Girls were treated for a mean (SD) of 3.4 (1.0) years and were followed up for 4.0 (1.2) years after the treatment was stopped. RESULTS: The rate of bone maturation decreased during treatment and the predicted adult height increased from 158.2 (7.4) cm to 163.9 (7.5) cm at the end of treatment (p < 0.001). When treatment was stopped bone maturation accelerated, resulting in a final height of 161.6 (7.0) cm, which was higher than the predicted adult height at the start of treatment (p < 0.001). Height at the start of treatment was the most important factor positively influencing final height (r = 0.75, p < 0.001). Bone age at cessation of treatment negatively influenced final height (r = -0.52, p = 0.03). A negative correlation between bone age and height increment after discontinuation of treatment was observed (r = -0.85, p = 0.001). Residual growth capacity was optimal when bone age on cessation of treatment was 12 to 12.5 years. Body mass index increased during treatment and remained high on cessation. At final height, the ratio of sitting height to subischial leg length was normal. Menarche occurred at 12.3 (1.1) years, and at a median (range) of 1.1 (0.4 to 2.6) years after treatment was stopped. The ovaries were normal on pelvic ultrasonography. CONCLUSIONS: Treatment of CPP with triptorelin increases final height, with normal body proportions, and seems to increase body mass index. The best results were achieved in girls who were taller at the start of treatment. Puberty was resumed after treatment, without the occurrence of polycystic ovaries.

Full text

PDF
292

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boepple P. A., Mansfield M. J., Wierman M. E., Rudlin C. R., Bode H. H., Crigler J. F., Jr, Crawford J. D., Crowley W. F., Jr Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev. 1986 Feb;7(1):24–33. doi: 10.1210/edrv-7-1-24. [DOI] [PubMed] [Google Scholar]
  2. Bourguignon J. P. Linear growth as a function of age at onset of puberty and sex steroid dosage: therapeutic implications. Endocr Rev. 1988 Nov;9(4):467–488. doi: 10.1210/edrv-9-4-467. [DOI] [PubMed] [Google Scholar]
  3. Bourguignon J. P., Van Vliet G., Vandeweghe M., Malvaux P., Vanderschueren-Lodeweyckx M., Craen M., Du Caju M. V., Ernould C. Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin). Eur J Pediatr. 1987 Nov;146(6):555–560. doi: 10.1007/BF02467352. [DOI] [PubMed] [Google Scholar]
  4. Brauner R., Adan L., Malandry F., Zantleifer D. Adult height in girls with idiopathic true precocious puberty. J Clin Endocrinol Metab. 1994 Aug;79(2):415–420. doi: 10.1210/jcem.79.2.8045957. [DOI] [PubMed] [Google Scholar]
  5. Comite F., Cassorla F., Barnes K. M., Hench K. D., Dwyer A., Skerda M. C., Loriaux D. L., Cutler G. B., Jr, Pescovitz O. H. Luteinizing hormone releasing hormone analogue therapy for central precocious puberty. Long-term effect on somatic growth, bone maturation, and predicted height. JAMA. 1986 May 16;255(19):2613–2616. [PubMed] [Google Scholar]
  6. Drop S. L., Odink R. J., Rouwé C., Otten B. J., Van Maarschalkerweerd M. W., Gons M., Bot A., Meradji M., de Jong F. H., Slijper F. M. The effect of treatment with an LH-RH agonist (Buserelin) on gonadal activity growth and bone maturation in children with central precocious puberty. Eur J Pediatr. 1987 May;146(3):272–278. doi: 10.1007/BF00716472. [DOI] [PubMed] [Google Scholar]
  7. Haber H. P., Mayer E. I. Ultrasound evaluation of uterine and ovarian size from birth to puberty. Pediatr Radiol. 1994;24(1):11–13. doi: 10.1007/BF02017650. [DOI] [PubMed] [Google Scholar]
  8. Jay N., Mansfield M. J., Blizzard R. M., Crowley W. F., Jr, Schoenfeld D., Rhubin L., Boepple P. A. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 1992 Sep;75(3):890–894. doi: 10.1210/jcem.75.3.1517382. [DOI] [PubMed] [Google Scholar]
  9. Jay N., Mansfield M. J., Blizzard R. M., Crowley W. F., Jr, Schoenfeld D., Rhubin L., Boepple P. A. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 1992 Sep;75(3):890–894. doi: 10.1210/jcem.75.3.1517382. [DOI] [PubMed] [Google Scholar]
  10. Kauli R., Kornreich L., Laron Z. Pubertal development, growth and final height in girls with sexual precocity after therapy with the GnRH analogue D-TRP-6-LHRH. A report on 15 girls, followed after cessation of gonadotrophin suppressive therapy. Horm Res. 1990;33(1):11–17. doi: 10.1159/000181437. [DOI] [PubMed] [Google Scholar]
  11. Kreiter M., Burstein S., Rosenfield R. L., Moll G. W., Jr, Cara J. F., Yousefzadeh D. K., Cuttler L., Levitsky L. L. Preserving adult height potential in girls with idiopathic true precocious puberty. J Pediatr. 1990 Sep;117(3):364–370. doi: 10.1016/s0022-3476(05)81074-1. [DOI] [PubMed] [Google Scholar]
  12. Lee P. A., Page J. G. Effects of leuprolide in the treatment of central precocious puberty. J Pediatr. 1989 Feb;114(2):321–324. doi: 10.1016/s0022-3476(89)80806-6. [DOI] [PubMed] [Google Scholar]
  13. Manasco P. K., Pescovitz O. H., Feuillan P. P., Hench K. D., Barnes K. M., Jones J., Hill S. C., Loriaux D. L., Cutler G. B., Jr Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab. 1988 Aug;67(2):368–372. doi: 10.1210/jcem-67-2-368. [DOI] [PubMed] [Google Scholar]
  14. Oerter K. E., Manasco P., Barnes K. M., Jones J., Hill S., Cutler G. B., Jr Adult height in precocious puberty after long-term treatment with deslorelin. J Clin Endocrinol Metab. 1991 Dec;73(6):1235–1240. doi: 10.1210/jcem-73-6-1235. [DOI] [PubMed] [Google Scholar]
  15. Oostdijk W., Hümmelink R., Odink R. J., Partsch C. J., Drop S. L., Lorenzen F., Sippell W. G., van der Velde E. A., Schultheiss H. Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist. Eur J Pediatr. 1990 Feb;149(5):308–313. doi: 10.1007/BF02171554. [DOI] [PubMed] [Google Scholar]
  16. Partsch C. J., Hümmelink R., Peter M., Sippell W. G., Oostdijk W., Odink R. J., Drop S. L. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group. Horm Res. 1993;39(3-4):111–117. doi: 10.1159/000182709. [DOI] [PubMed] [Google Scholar]
  17. Paul D., Conte F. A., Grumbach M. M., Kaplan S. L. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab. 1995 Feb;80(2):546–551. doi: 10.1210/jcem.80.2.7852518. [DOI] [PubMed] [Google Scholar]
  18. Sigurjonsdottir T. J., Hayles A. B. Precocious puberty. A report of 96 cases. Am J Dis Child. 1968 Mar;115(3):309–321. doi: 10.1001/archpedi.1968.02100010311003. [DOI] [PubMed] [Google Scholar]
  19. Stanhope R., Preece M. A., Grant D. B., Brook C. G. New concepts of the growth spurt of puberty. Acta Paediatr Scand Suppl. 1988;347:30–37. [PubMed] [Google Scholar]
  20. Stanhope R., Pringle P. J., Brook C. G. Growth, growth hormone and sex steroid secretion in girls with central precocious puberty treated with a gonadotrophin releasing hormone (GnRH) analogue. Acta Paediatr Scand. 1988 Jul;77(4):525–530. doi: 10.1111/j.1651-2227.1988.tb10694.x. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES